Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

CEO

Dr. Iraj Ali Ph.D.

Employees

204

Country

United Kingdom

ISIN

US00449L1026

Listings

698.MU

STU

698.STU

0 Comments

Share your thoughts

FAQ

What is Achilles Therapeutics stock price today?▼

The current price of 698.MU is €1.36 EUR — it has increased by +0% in the past 24 hours. Watch Achilles Therapeutics stock price performance more closely on the chart.

What is Achilles Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Achilles Therapeutics stocks are traded under the ticker 698.MU.

How many employees does Achilles Therapeutics have?▼

As of May 11, 2026, the company has 204 employees.

In which sector is Achilles Therapeutics located?▼

Achilles Therapeutics operates in the Other sector.

When did Achilles Therapeutics complete a stock split?▼

Achilles Therapeutics has not had any recent stock splits.

Where is Achilles Therapeutics headquartered?▼

Achilles Therapeutics is headquartered in London, United Kingdom.